Research Article
Safety of Intravenous Immunoglobulin (Tegeline®), Administered at Home in Patients with Autoimmune Disease: Results of a French Study
Table 1
Patient characteristics (safety population,
).
| | Patient number (percentage) |
| Sex | | Female | 18 (39.1%) | Male | 28 (60.9%) | (years) | | Mean (SD) | 52.4 (13.24) | Median | 53 | (Minimum/maximum) | (25–79) | Weight (kg) in hospital versus at home | | Mean (SD) | 74.3 (14.6) versus 74.5 (14.5) | Median | 74.2 versus 75 | (Minimum/maximum) | (49–127) versus (50–126) | Autoimmune diseases | | Motor multifocal neuropathy (MMN) | 21 (45.7%) | Chronic inflammatory demyelinating polyneuropathy including Lewis-Sumner syndrome | 12 (26.1%) | Polymyositis | 3 (6.5%) | Dermatomyositis | 3 (6.5%) | Body inclusion myositis | 3 (6.5%) | Sclerosis with myopathy | 1 (2.2%) | Gougerot-Sjogren syndrome with neurological forms | 1 (2.2%) | Myasthenia gravis | 1 (2.2%) | Cutaneous polyarteritis nodosa | 1 (2.2%) | Family situation | | Living in a couple or in a family setting | 41 (89.1%) | Living alone | 5 (10.9%) | Professional activity at the time of administration of the cycles in hospital | | Professional activity | 19 (42.2%) | Without professional activity | 26 (57.8%) | (i) Retired person | 17 | (ii) Disabled person | 6 | (iii) Sick leave | 1 | (iv) Other | 2 |
|
|
SD: standard deviation. age = patient’s age at the time of the last hospital-based cycle of Tegeline before starting treatment at home. |